CASTOR2

Across TCGA pan-cancer cohorts, CASTOR2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CASTOR2 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CASTOR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASTOR2 expression acts as an unfavorable survival marker.

THYM, LIHC, and UCEC are the cancer types where CASTOR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BRCA	OS	Median	All	0.844	0.963	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CASTOR2–THYM (OS)

Open the THYM breakdown →